USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Technology development and pre-clinical testing of a novel…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
91185
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
0946099
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Insera Therapeutics Inc.
1560 Arcola Avenue Sacramento, CA 95835-1637
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: SBIR Phase I: Technology development and pre-clinical testing of a novel minimally invasive catheter-based blood clot-retrieval and clot-filtering device
Agency: NSF
Contract: 0946099
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project aims to develop the industry's first catheter-based stroke treatment device that serves both as a blood clot-retrieval as well as a clot-filtering device. Stroke is a major economic burden on the tax payer costing $65.5 billion/year. The mean lifetime healthcare cost for a stroke patient is $140,048. The first step in the treatment of acute stroke is the removal of the blood clot to restore vital blood supply to the brain. However, existing catheter-based therapies have only shown modest success in removing clots and are effective in less than two-thirds of stroke patients. In addition, these therapies can release debris into the blood stream causing further strokes. The research objective of this project is to perform pre-clinical testing of a more effective clot-retrieval device and a clot-filtering device that can make existing stroke therapies safer. The broader impacts of this research are far-reaching as the global stroke burden is staggering. Each year 780,000 strokes occur in the US and nearly 20.5 million strokes occur worldwide. This project is projected to yield important outcomes. First, the efficacy of this clot-retrieval device in removing blood clots will be confirmed. Second, the efficacy of this clot-filtering device will be confirmed in preventing release of debris during catheter-based stroke treatments thereby making these procedures safer. This public-private partnership is expected to have an important positive impact on the community by saving lives, creating jobs, and decreasing the economic burden of stroke on the tax payer.

Principal Investigator:

Vallabh Janardhan
MD
9168490945
vallabh@inseratherapeutics.com

Business Contact:

Vallabh Janardhan
MD
9168490945
vallabh@inseratherapeutics.com
Small Business Information at Submission:

Insera Therapeutics Inc.
1560 Arcola Avenue Sacramento, CA 95835

EIN/Tax ID: 260261106
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No